Relmada’s rapid-acting NMDA depression drug expected to fail second Phase 3

Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Challenges and opportunities for better lung cancer care for the elderly

A new editorial paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 15, Issue 17,

September 29, 2023

Natural antioxidants could delay age-related decline in male testosterone production

Natural polyphenolic compounds to enhance testosterone production and prevent age-related hypogonadism in aging males.

June 12, 2024

ADHD Tied to Keratoconus in Males

Attention deficit-hyperactivity disorder (ADHD) was associated with a diagnosis of keratoconus in males, according to an Israeli population-based cross-sectional study. Looking at the medical records

November 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.